Integra LifeSciences Holdings Corp

Integra LifeSciences Holdings Corp Stock Forecast & Price Prediction

Live Integra LifeSciences Holdings Corp Stock (IART) Price
$45.2

6

Ratings

  • Buy 3
  • Hold 1
  • Sell 2
Disclaimer : The analyst ratings and price forecast data are provided by Tradefeeds. The data is sourced from Wall Street analysts and other experienced experts. The figures presented are solely a forecast and not a guarantee of future price performance. The information presented is not a recommendation to buy or sell the stock.

Stock Price

$45.2

P/E Ratio

36.92

Volume Traded Today

$600,853

Dividend

Dividends not available for IART

52 Week High/low

59.33/33.44

Integra LifeSciences Holdings Corp Market Cap

$3.52B

🛑 Alert: These ten stocks could have higher potential than $IART 🛑

Before you buy IART you’ll want to see this list of ten stocks that have huge potential. Want to see if IART made the cut? Enter your email below

IART Summary

Based on ratings from 6 stock analysts, the Integra LifeSciences Holdings Corp stock price is expected to increase by 2.5% in 12 months. This is calculated by using the average 12-month stock price forecast for Integra LifeSciences Holdings Corp. The lowest target is $38.00 and the highest is $55.00. Please note analyst price targets are not guaranteed and could be missed completely.

IART Analyst Ratings

IART is a stock in Health Care which has been forecasted to be worth $46.33 as an average. On the higher end, the forecast price is $55.00 USD by david turkaly from JMP Securities and on the lower end IART is forecasted to be $38.00 by robbie marcus from J.P. Morgan.

IART stock forecast by analyst

Analyst/Firm

Rating

Price Target

Change

Date

matthew taylor
Jefferies

Buy

$50.0

maintained

Feb 5, 2024
vik chopra
Wells Fargo

Buy

$49.0

maintained

Feb 5, 2024
ryan zimmerman
BTIG

Hold

None

maintained

Jan 1, 2024
richard newitter
Truist Financial

Hold

$46.0

maintained

Dec 22, 2023
david turkaly
JMP Securities

Buy

$55.0

reiterated

Dec 14, 2023
craig bijou
Bank of America Securities

Sell

$40.0

maintained

Dec 13, 2023
joanne wuensch
Citi

Sell

$38.0

maintained

Dec 11, 2023
kristen stewart
C.L. King

Buy

$50.0

initiatedcoverage

Nov 14, 2023
robbie marcus
J.P. Morgan

Sell

$38.0

maintained

Oct 26, 2023
drew ranieri
Morgan Stanley

Sell

$44.0

downgraded

Aug 24, 2023
steven lichtman
Oppenheimer

Buy

$53.0

maintained

Jul 28, 2023
matthew o'brien
Piper Sandler

Hold

$44.0

maintained

Jun 26, 2023
david toung
Argus Research

Hold

None

downgraded

Jun 8, 2023
larry biegelsen
Wells Fargo

Hold

$47.0

maintained

May 24, 2023
jayson bedford
Raymond James

Hold

None

maintained

Feb 23, 2023
robert marcus
J.P. Morgan

Hold

$75.0

upgraded

Dec 17, 2021
matt miksic
Credit Suisse

Buy

$87.0

maintained

Nov 3, 2021
anthony petrone
Jefferies

Buy

$86.0

rated

May 20, 2021
shagun singh chadha
RBC Capital

Hold

$74.0

maintained

Apr 29, 2021
brandon henry
RBC Capital

Hold

$62.0

maintained

Oct 25, 2019

IART Company Information

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

IART
Integra LifeSciences Holdings Corp (IART)

When did it IPO

N/A

Staff Count

3,722

Country

United States

Sector/Industry

Healthcare/Medical Devices

CEO

Mr. Jan De Witte

Market Cap

$3.52B

Integra LifeSciences Holdings Corp (IART) Financial Data

In 2023, IART generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that IART's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

N/A

Revenue From 2021

N/A

0.00 %
From Previous Year

Revenue From 2022

N/A

0.00 %
From Previous Year

Revenue From 2023

N/A

0.00 %
From Previous Year
  • Revenue TTM $1.54B
  • Operating Margin TTM 14.9%
  • Gross profit TTM $970.3M
  • Return on assets TTM 4.4%
  • Return on equity TTM 6.1%
  • Profit Margin 6.5%
  • Book Value Per Share 19.96%
  • Market capitalisation $3.52B
  • Revenue for 2021 N/A
  • Revenue for 2022 N/A
  • Revenue for 2023 N/A
  • EPS this year (TTM) $1.22

Integra LifeSciences Holdings Corp (IART) Latest News

... ...

Similar Stocks to Integra LifeSciences Holdings Corp - IART

🛑 Alert: These ten stocks could have higher potential than $IART 🛑

Before you buy IART you’ll want to see this list of ten stocks that have huge potential. Want to see if IART made the cut? Enter your email below

...

IART Frequently asked questions

The highest forecasted price for IART is $55.00 from david turkaly at JMP Securities.

The lowest forecasted price for IART is $38.00 from robbie marcus from J.P. Morgan

The IART analyst ratings consensus are 3 buy ratings, 1 hold ratings, and 2 sell ratings.